PT - JOURNAL ARTICLE AU - J Corrado AU - SJ Halpin AU - N Preston AU - D Whiteside AU - R Tarrant AU - J Davison AU - RJ O’Connor AU - AJ Casson AU - M Sivan TI - HEART rate variability biofeedback for LOng Covid symptoms (HEARTLOC): protocol for a feasibility study AID - 10.1101/2022.06.23.22276821 DP - 2022 Jan 01 TA - medRxiv PG - 2022.06.23.22276821 4099 - http://medrxiv.org/content/early/2022/06/27/2022.06.23.22276821.short 4100 - http://medrxiv.org/content/early/2022/06/27/2022.06.23.22276821.full AB - Introduction Long covid (LC), also known as Post-COVID-19 syndrome, refers to symptoms persisting 12 weeks after COVID-19 infection. It affects up to 1 in 7 people contracting the illness and causes a wide range of symptoms, including fatigue, breathlessness, palpitations, dizziness, pain and brain fog. Many of these symptoms can be linked to dysautonomia or dysregulation of the autonomic nervous system after SARS-CoV2 infection. This study aims to test the feasibility and estimate the efficacy, of the Heart Rate Variability Biofeedback (HRV-B) technique via a standardised slow diaphragmatic breathing programme in individuals with LC.Methods and Analysis 30 adult LC patients with symptoms of palpitations or dizziness and an abnormal NASA Lean Test (NLT) will be selected from a specialist Long COVID rehabilitation service. They will undergo a 4-week HRV-B intervention using a Polar chest strap device linked to the Elite HRV phone application while undertaking the breathing exercise technique for two 10-min periods every day for at least 5 days a week. Quantitative data will be gathered during the study period using: HRV data from the chest strap and wrist-worn Fitbit, the modified COVID-19 Yorkshire Rehabilitation Scale (C19-YRSm), composite autonomic symptom score (COMPASS 31), World Health Organisation Disability Assessment Schedule (WHODAS 2.0) and EQ-5D-5L health related quality of life measures. Qualitative feedback on user experience and feasibility of using the technology in a home setting will also be gathered. Standard statistical tests for correlation and significant difference will be used to analyse the quantitate data.Ethics and Dissemination The study has received ethical approval from Health Research Authority (HRA) Leicester South Research Ethics Committee (21/EM/0271). Dissemination plans include academic and lay publications.Study Registration Clinicaltrials.gov No: NCT05228665Strengths and limitations of the studyTo our knowledge, this is the first study of HRVB in long covid and will provide new information regarding the feasibility of the technology-based intervention in this condition.The estimation of efficacy will determine the scope and sample size for a larger controlled trial in the condition that currently has no definitive treatmentsThe study will provide preliminary evidence on the correlation between long covid symptoms and dysautonomia.The limitation of this study is the small sample size of 30 participants which might not give an accurate estimate of efficacy.HRV-B is a technology-based intervention, therefore its take-up could be limited in those with a lack of experience in using digital technology in daily life, particularly those from less privileged backgrounds.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT05228665Funding StatementThis research is supported by IAA EPSRC [Ref 112538] with University of Leeds as the sponsor organisation and the Leeds Community Healthcare NHS Trust Covid Rehabilitation service as the research site organisation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study has received ethical approval from Health Research Authority (HRA) Leicester South Research Ethics Committee (21/EM/0271).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors